Table 8 NCV for HSCT patients
MLD type | Symptom status | Follow-up timepoint after HSCT | Outcome definition | n/N (%) | Source |
|---|---|---|---|---|---|
LI | Mixed | NR | No. with worsening NCV^ | 1/3 (33.3%)~ | Boucher [21]—R |
LI | Mixed | NR | No. with worsening NCV* | 5/8 (62.5%) | Martin [23]—R |
J | Mixed | NR | No. with worsening NCV^ | 10/15 (66.7%)~ | Boucher [21]—R |
J | Mixed | NR | No. with worsening NCV * | 4/12 (33.3%) | Martin [23]—R |
LI | Mixed | NR | No. with stabilised NCV^ | 2/3 (66.7%)~ | Boucher [21]—R |
LI | Mixed | NR | No. with NCV stabilised*^ | 3/8 (37.5%) | Martin [23]—R |
J | Mixed | NR | No. with stabilised NCV^ | 5/15 (33.3%)~ | Boucher [21]—R |
J | Mixed | NR | No. with NCV stabilised*^ | 8/12 (66.7%) | Martin [23]—R |